Teva buys into genomics to bolster its in-house R&D

Israeli pharma giant Teva Pharmaceutical ($TEVA) is investing in Cambridge, MA's Immuneering, taking up a stake in the genomics upstart and tapping its expertise to help guide internal drug development. Teva has acquired a 51% share of its partner, the companies said, at the same time agreeing to collaborate on personalized treatments for CNS ailments. Teva plans to use Immuneering's proprietary analytics platform to hone its R&D in the field, relying on its partner to help it make decisions in early development and match the right patients to their ideal therapies, the company said. More